Citigroup Inc Puma Biotechnology, Inc. Transaction History

Citigroup Inc

$163 Billion
Q4 2024

A detailed history of Citigroup Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Citigroup Inc holds 33,261 shares of PBYI stock, worth $95,791. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,261

Previous 30,048 10.69%

Holding current value

$95,791

Previous $76,000 32.89%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$2.42 - $3.39 $7,775 - $10,892	3,213 Added 10.69%	33,261 $101,000
Q3 2024 Nov 12, 2024	BUY	$2.25 - $4.03 $22,923 - $41,057	10,188 Added 51.3%	30,048 $76,000
Q2 2024 Aug 12, 2024	SELL	$2.92 - $5.83 $322,989 - $644,873	-110,613 Reduced 84.78%	19,860 $64,000
Q1 2024 May 10, 2024	SELL	$4.29 - $7.4 $174,088 - $300,292	-40,580 Reduced 23.72%	130,473 $691,000
Q4 2023 Feb 09, 2024	BUY	$2.23 - $4.49 $158,967 - $320,074	71,286 Added 71.45%	171,053 $740,000
Q3 2023 Nov 09, 2023	BUY	$2.63 - $4.09 $262,387 - $408,047	99,767 New	99,767 $262,000
Q4 2022 Feb 09, 2023	BUY	$2.12 - $5.08 $54,961 - $131,699	25,925 Added 4730.84%	26,473 $111,000
Q3 2022 Nov 10, 2022	SELL	$2.27 - $3.84 $973 - $1,647	-429 Reduced 43.91%	548 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.64 - $3.3 $1,815 - $3,653	-1,107 Reduced 53.12%	977 $3,000
Q1 2022 May 12, 2022	SELL	$2.13 - $3.24 $15,210 - $23,136	-7,141 Reduced 77.41%	2,084 $6,000
Q4 2021 Feb 10, 2022	BUY	$2.85 - $6.58 $8,874 - $20,490	3,114 Added 50.96%	9,225 $28,000
Q3 2021 Nov 10, 2021	BUY	$6.63 - $9.39 $40,515 - $57,382	6,111 New	6,111 $43,000

Others Institutions Holding PBYI

# of Institutions

110

Shares Held

28.3M

Call Options Held

27.9K

Put Options Held

3.4K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $131M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account